This website uses cookies to ensure you get the best experience on our website.

Rarity Bioscience and selected partners use cookies and similar technologies to ensure you get the best experience on this website. If you consent to it, we will use cookies for analytics purposes.

See our Cookie Policy to read more about the cookies we set.

You can withdraw and manage your consent at any time, by clicking "Manage cookies" at the bottom of each website page.

Select which cookies you accept

On this site, we always set cookies that are strictly necessary, meaning they are necessary for the site to function properly.

If you consent to it, we will also set other types of cookies. You can provide or withdraw your consent to the different types of cookies using the toggles below. You can change or withdraw your consent at any time, by clicking the link “Manage Cookies”, which is always available at the bottom of the site.

To learn more about what the different types of cookies do, how your data is used when they are set etc, see our Cookie Policy.

These cookies are necessary to make the site work properly, and are always set when you visit the site.

Vendors Teamtailor

These cookies collect information to help us understand how the site is being used.

Vendors Teamtailor
Rarity Bioscience career site

Our journey has just started

Connect

Vision & Mission

Our vision is to democratize mutation detection.

Our mission is to improve clinical decisions and patient outcome by offering fast, sensitive, and reliable mutation detection technology at the right time.

At Rarity Bioscience sustainability is a belief that we embody in our products and services as well as in our workplace. Do you want to know more about how we are contributing to sustainability from a health, social and economical perspective? 

Rarity Bioscience

About Rarity Bioscience

 

Rarity Bioscience provides ultrasensitive multiplex assays for detecting rare nucleic acid sequences in biological samples like liquid biopsies. Our main application is our superRCA technology platform, which permits read-out based on flow cytometry, an already existing instrumentation in many labs.

The company was founded in 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology and a member of Professor Ulf Landegren’s team at the Department of Immunology, Genetics and Pathology at Uppsala University.